Revelation Biosciences exercises warrants for $3.8M in gross proceeds

Revelation Biosciences announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,548,060 shares of common stock, issued by the company on February 5, 2024, at the reduced exercise price of $1.50 per share. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to an effective registration statement on Form S-1. The closing of the offering is expected to occur on or about August 22, 2024, subject to satisfaction of customary closing conditions. Roth Capital Partners is acting as the company’s financial advisor for this transaction.